Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

sanofi pasteur - franta - vaccin meningococic conjugat de grup a,c,wsi y - sol. inj. - vaccinuri bacteriene vaccinuri meningococice

Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

gsk vaccines s.r.l. - italia - vaccin meningococic conjugat de grup a,c,w135 dacĂ y - pulb. si sol. pt. sol. inj. - vaccinuri bacteriene vaccinuri meningococice

Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing belgium n.v. - belgia - vaccin meningococic conjugat de grup a,c,w135 dacĂ y - pulb.+solv. pt. sol. inj. in seringa preumpluta - vaccinuri bacteriene vaccinuri meningococice

Romania - Tiếng Romania - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

pfizer manufacturing belgium n.v. - belgia - vaccin meningococic grup b (recombinant, adsorbit) - susp. inj. in seringa preumpluta - 60micrograme/60micrograme - vaccinuri bacteriene vaccinuri meningococice

Moldova - Tiếng Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glaxosmithkline biologicals s.a. - vaccin difteric, tetanic, pertussis, hepatitic b, poliomielitic și haemophilus influenzae tip b - ... - pulbere şi suspensie pentru suspensie injectabilă - 1 doză

Moldova - Tiếng Romania - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

glaxosmithkline biologicals s.a. - vaccin rujeolic, oreionic, rubeolic, viu atenuat - pulbere şi solvent pentru soluţie injectabilă - 1 doză

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

alexion europe sas - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - soliris este indicat la adulți și copii pentru tratamentul:hemoglobinurie paroxistică nocturnă (hpn). dovezi de beneficii clinice este demonstrată la pacienții cu hemoliză cu simptom clinic(s) indică un grad înalt de activitate a bolii, indiferent de transfuzie istorie (a se vedea secțiunea 5. atipic sindrom hemolitic-uremic (ahus). soliris este indicat la adulți pentru tratamentul:refractare generalizate miastenia gravis (gmg) la pacienții care sunt anti-receptorilor de acetilcolină (achr) anticorpi-pozitiv (a se vedea secțiunea 5. oftalmoneuromielită optica tulburare de spectru (nmosd) la pacienții care sunt anti-aquaporin-4 (aqp4) anticorpi pozitiv cu un curs recurente ale bolii.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Liên Minh Châu Âu - Tiếng Romania - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dovezi de beneficii clinice este demonstrată la pacienții cu hemoliză cu simptom clinic(s) indică un grad înalt de activitate a bolii, indiferent de transfuzie istorie (a se vedea secțiunea 5.